XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants
Jain, S.; Kumar, S.; Lai, L.; Linderman, S.; Malik, A. A.; Ellis, M. L.; Godbole, S.; Solis, D.; Sahoo, M. K.; Bechnak, K.; Paredes, I.; Tanios, R.; Kazzi, B.; Dib, S. M.; Litvack, M. B.; Wimalsena, S. T.; Ciric, C.; Rostad, C.; West, R.; Teng, I.-T.; Wang, D.; Kwong, P. D.; Rouphael, N.; Pinsky, B. A.; Douek, D. C.; Wrammert, J.; Moreno, A.; Suthar, M. S.
Show abstract
The rapid emergence of divergent SARS-CoV-2 variants has led to an update of the COVID-19 booster vaccine to a monovalent version containing the XBB.1.5 spike. To determine the neutralization breadth following booster immunization, we collected blood samples from 24 individuals pre- and post-XBB.1.5 mRNA booster vaccination ([~]1 month). The XBB.1.5 booster improved both neutralizing activity against the ancestral SARS-CoV-2 strain (WA1) and the circulating Omicron variants, including EG.5.1, HK.3, HV.1, XBB.1.5 and JN.1. Relative to the pre-boost titers, the XBB.1.5 monovalent booster induced greater total IgG and IgG subclass binding, particular IgG4, to the XBB.1.5 spike as compared to the WA1 spike. We evaluated antigen-specific memory B cells (MBCs) using either spike or receptor binding domain (RBD) probes and found that the monovalent booster largely increases non-RBD cross-reactive MBCs. These data suggest that the XBB.1.5 monovalent booster induces cross-reactive antibodies that neutralize XBB.1.5 and related Omicron variants.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination 96%
- Longitudinal cellular and humoral immune responses following Covid-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar. 96%
- Memory B cell and humoral responses elicited by Sputnik V in naïve and COVID-19-recovered vaccine recipients 96%
Similar papers in this journal
Similar papers in this journal
- Effect of booster vaccination against Delta and Omicron variants in Iceland 95%
- Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report 95%
- Distinct COVID-19 vaccine combinations result in divergent immune responses 95%
Similar papers in this journal
- GRAd-COV2 vaccine provides potent and durable immunity in randomised placebo-controlled phase 2 trial (COVITAR) 96%
- Protective antibodies and T cell responses to Omicron variant three months after the booster dose of BNT162b2 vaccine 95%
- Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine 95%
Similar papers in this journal
- Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting 95%
- Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial 95%
- Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.